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accepted Septembeew vessel formation inside the arterial wall and atherosclerotic plaques plays a critical role in pathogenesis of
heart attacks and strokes. The 2 known mechanisms resulting in the formation of new vessels within the plaque
are local ischemia and inﬂammation. Blood monocytes play an important role in both processes. First, they express
receptors for vascular endothelial growth factor and some of them may serve as circulating ancestors of
endothelial cells. Second, monocytes are associated with inﬂammation by synthesis of inﬂammatory molecules
following their activation (e.g., after stimulation of Toll-like receptors). Neovascularization is a reparative response
to ischemia, and includes 3 processes: angiogenesis, arteriogenesis, and vasculogenesis. Angiogenesis, the
formation of new capillary vessels is known to occur in response to a hypoxic environment. The interaction between
leukocytes and vascular wall via overexpression of various molecules facilitates the migration of inﬂammatory cells
into the plaque microenvironment. Monocytes are intimately involved in tissue damage and repair and an
imbalance of these processes may have detrimental consequences for plaque development and stability.
Importantly, monocytes are comprised of distinct subsets with different cell surface markers and functional
characteristics and this heterogeneity may be relevant to angiogenic processes in atherosclerosis. The aim of this
review article is to present an overview of the available evidence supporting a role for monocytes in angiogenesis and
atherosclerosis. (J Am Coll Cardiol 2014;63:1–11) ª 2014 by the American College of Cardiology FoundationAtherosclerosis is the primary cause for stroke and coronary
artery disease in the Western World. It is a chronic
inﬂammatory process characterized by development of lipid
rich plaques within the layers of the arterial wall (Fig. 1).
Within this thickened wall is where foam cells, monocyte
derived lipid laden macrophages have been recognized (1).
The formation of atherosclerotic plaque is a series of events
that is initiated with lipid accumulation (fatty streak) fol-
lowed by monocyte inﬁltration and the lipid core formation.
Advanced lesions can obstruct arterial lumen, but at any
stage atherosclerotic plaque may be complicated by rupture
causing a hypoxia/ischemia of the downstream tissues and
subsequent vascular complications.
Unhealthy lifestyles, diabetes, obesity, hypertension are
still common contributors to the atherogenesis and devel-
opment of unfavorable events thus prompting identiﬁcation
of new therapeutic targets (2). This is particularly true as
current treatment modalities such not all patients are suit-
able for adequate coronary artery bypass grafting or angio-
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r 16, 2013.previously triggers numerous pathological pathways in-
volving a number of molecular processes, which include
lipid metabolism, coagulation, apoptosis, hypoxia, and the
immune response (3).
The body’s natural response to ischemia is a reparative
mechanism summarized by the term neovascularization.
Neovascularization includes 3 processes: angiogenesis, ar-
teriogenesis, and vasculogenesis. The formation of new
capillary vessels, angiogenesis, has been extensively re-
searched and occurs in response to a hypoxic environment
(4). Progression and expansion of already existing collateral
smooth muscle-type vessels or arteriogenesis, is believed to
be a mechanism of organ preservation in the presence of
vascular occlusion. Vasculogenesis or new vessel growth
derived from progenitor/stem cells has been demonstrated
in both the adult and embryo (5). Understanding these
processes of vessel adaptation or formation is fundamental
for developing new therapeutic strategies.
Inﬂammation has been shown to be an essential factor
accompanying both the angiogenic and atherogenic path-
ways (5). Monocyte-derived macrophages play a pivotal
role in lipid deposition and progression of atherosclerosis,
but they are also implicated in the genesis of new vessels
(6). The aim of this article is to present an overview of the
available evidence supporting the role of monocytes in
angiogenesis.
Figure 1 Angiogenesis and
Site of occurrence within the arteria
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2Search Strategy
We searched the following elec-
tronic databases (limiting the
search from 1970 to July 2010):
Pubmed, Medline, EMBASE,
and Cochrane Reviews. Given
the enormity of this subject area,
we have focused on areas of
particular relevance to angiogen-
esis and the role of monocytes
in neovascularization. The key
words used were angiogenesis,
neovascularization, vasculogenesis,
angiopoietin, vascular endothelial
growth factor (VEGF), Tie2, mono-
cytes, and monocyte subsets.Atherogenesis and
Plaque Neovascularization
Atherosclerosis is characterized
by monocyte adherence to en-
dothelium cell, migration intothe arterial wall, and lipid accumulation (7). The earliest
detectable atherosclerotic change is pathological intimal
thickening (8).
Enlargement of the plaque results in intraplaque
hypoxia that triggers the inﬂammatory cell inﬁltration,
thus promoting local neovascularization (9). Interestingly,Inﬂammation
l wall/vessel. VEGF ¼ vascular endothelial growth facalthough intimal thickening is believed to be an early
surrogate marker for atherosclerosis, pathological neo-
vascularization is implicated in both early and late stages of
the disease (9). For example, in experimental studies on
hypercholesterolemia, adventitial neovascularization in the
coronary arteries has been shown to be present even before
the actual plaque (protrusion into the lumen) begins to
develop (9). Two instrumental factors inﬂuencing the
initiation of intra-arterial neovascularization are local
ischemia and either local or systemic inﬂammatory burden.
Pathological thickening of the intima greater than 100 ml
increases the distance between the lumen and the inner parts
of the vascular wall, thus impairing the supply with oxygen
and nutrition. As vascular disease ensures excessive vessel
wall thickness, proliferation of the vasa vasorum and in-
timal neovascularization is observed. Indeed, the degree of
adventitial neovascularization has recently been demon-
strated to be associated with intima-media thickness (10).
Evidence of the role of ischemia in the initiation of
angiogenesis stems from the demonstration of increased
levels of hypoxia inducible factor (HIF-1), which ultimately
promotes VEGF production (4,11). As a potent stimulator
of angiogenesis, VEGF is consequently able to create a local
pro-angiogenic environment by mobilizing endothelial
progenitor cells (EPCs) (Table 1) (12). Furthermore,
aggressive plaque development and accelerated neovascu-
larization of the vascular wall have been seen following the
administration of VEGF in laboratory experiments (13).
Hypoxia-independent pathways triggered by an inﬂam-
matory stimulus within the vascular wall have also beentor.
Table 1 Angiogenesis Inhibitors and Stimulators
Stimulators Inhibitors
VEGF Angiostatin
IL-6 TGF-b
TNF Interferon
bFGF IL-12
PDGF Antithrombin III
bFGF ¼ basic ﬁbroblast growth factor; IL ¼ interleukin; PDGF ¼ platelet-derived growth factor;
TGF ¼ transforming growth factor; TNF ¼ tumor necrosis factor; VEGF ¼ vascular endothelial
growth factor.
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3recognized as modulators of angiogenesis (14). The density
of intraplaque vessels corresponds to the focal accumu-
lation of inﬂammatory cells (i.e., monocytes/macrophages)
forming a pathological circle: angiogenesis > mobilization
of inﬂammatory cells > angiogenesis (15). Switching bet-
ween this inﬂammatory/angiogenic cascade may be res-
ponsible for enhanced plaque progression related to local
plaque inﬂammation and plaque destabilization. This
hypothesis is supported by increased expression of leukocyte
adhesion molecules, such as vascular adhesion molecule-1
(VCAM) and intracellular adhesion molecule-1 (ICAM),
on the intimal side of vascular endothelium as opposed
to the adventitial side (16). Therefore, these observations
allude to the notion that the presence of these adhesion
molecules on the newly formed vessels is associated with the
enhanced accumulation of leukocytes (16).
While association of the development and progression of
atherosclerosis with macrophages has long been recognized,
the function of their blood ancestors, monocytes, was less
addressed. However, a potential link between monocytes
and abnormal plaque angiogenesis has a strong biological
justiﬁcation. Prior to discussing angiogenesis, an overall
understanding of vasculogenesis (new-vessel formation) and
its relationship to EPCs needs to be addressed.
Vasculogenesis
Vascular system development in the embryo is termed vasculo-
genesis. The ﬁrst endothelial and hematopoietic cells
are derived from a process whereby blood islands are for-
med from hemangioblasts, otherwise known as mesodermal
progenitors in the embryonic yolk sac. These islands of cells
differentiate and proliferate from precursors of the vascular
wall, angioblasts, which further give origin to endothelial
cells (17). Vascular development occurs, as these endo-
thelial cells form the ﬁrst primitive tubes/vessels. Impor-
tantly, it is at this point when both VEGF and basic
ﬁbroblast growth factor (bFGF) (a critical angiogenic
factor), starts to play a role in the process (18). Activation of
bFGF receptors on endothelial cells by bFGF increases the
endothelial cell motility, proliferation and proteinase activity
(19). bFGF can also induce VEGF expression via HIF-1a
activation as seen in a study by Shi et al. (20), who showed
that HIF-1a induction by bFGF seemed to be an inde-
pendent pathway triggering VEGF expression in breastcancer. Bovine studies have shown endothelial cell prolifer-
ation and capillary formation in the presence of bFGF and
VEGF (21).
The identiﬁcation of EPCs in the adult has led to efforts
to understand their contribution to the adult angiogenic
processes. However, it must be mentioned that there is
much debate regarding methods of EPC quantiﬁcation and
standardizations. This is due to a signiﬁcant cell overlap
observed and the presence of the progenitors at different
stages of maturation (22). Recently, Sozer et al. (23) have
demonstrated that monocytes and EPCs share many char-
acteristics while other less differentiated primitive cells
produce endothelial cells only in vitro. Further delineation of
their phenotype is required.
Angiogenesis
The development of new vasculature, particularly the
formation of new capillaries from endothelial cells that
“sprout” from existing blood vessels is of importance for
a number of pathological and homeostatic processes. It is
also fundamental for the embryonic development. Tumor
research, the important ﬁeld for angiogenic studies, has not
only suggested a pathological signiﬁcance of the angiogenic
process in cancer but also led to further efforts to investigate
these processes in biological mechanisms of wound healing,
ovulation, and tissue repair (24).
Naturally healthy tissue requires a supply of nutrients and
oxygen. Also the restoration of tissue under ischemic
conditions and tumor growth are dependent on new vessel
formation for the supply of nutrients and the removal of
degradation products. This understanding of an angiogenic
process has led to a vast number of studies on therapeutic
approaches to the management of vascular disorders. The
primary pathological focus of this evidence has been on
understanding the atherosclerosis-related angiogenesis in
plaque formation, and the inhibition of neovascularization
thereby attempting to slow the disease progression (24).
Interestingly, the main laboratory approach used for
understanding of the mechanisms of atherosclerosis-related
angiogenesis was based on analysis of ischemic tissues in
the presence of pre-existing plaque stenosis as opposed to
long-term studies on the development and progression of
the disease. For example, a study by McCarthy et al. (25)
suggested an association between symptomatic carotid
disease (plaque) and the presence of intraplaque neo-
vascularization. However this study recruited patients who
had pre-existing carotid stenosis and did not study patients
who were initially carotid plaque free and developed stenosis
over a number of years (25). This lack of evidence on early
changes and pathological mechanisms has driven the need
for non-invasive approaches to detect neovascularization,
such as carotid contrast ultrasonography.
The initiating factor of angiogenesis is a hypoxic envi-
ronment, often associated with tissue inﬂammation (26).
The entire pathway is thought to be stimulated by HIF-1a.
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4In the ischemic environment HIF-1a, escapes degradation
due to its transcription being down-regulated and its ability
to bind other factors (e.g., HIF-1b) activating target genes
involved in angiogenesis (27). Interestingly a number of
growth factors (e.g., platelet-derived growth factor, and
bFGF) also share this regulatory hypoxic driven pathway
(28). VEGF, an essential angiogenic modulator has been
shown in several in vivo models to induce a strong con-
comitant angiogenic cascade with HIF-1 (11). VEGF
expressed by macrophages and T-lymphocytes stimulates
endothelial cells to produce monocyte chemoattractant
protein (MCP)-1, hence attracting monocytes and en-
hancing cell migration by increasing the permeability of
the endothelial layer (29,30). Embryologically, the absence
of VEGF results in early death due to abnormal blood
vessel growth, demonstrating a common link between the
physiological and pathological angiogenic pathways (31).
The sprouting of new vessels from pre-existing vascula-
ture is known as angiogenesis. Angiogenic signals from
surrounding cells lead to vasodilatation and an increase in
vascular permeability (27,32). Digestive enzymes such as
collagenase and matrix metalloproteinases partially destroy
the basement membrane (33). The plasma proteins then
form a ﬁbrin rich matrix, with a lumen forming in the
proliferating capillary when the activated endothelial cells
migrate towards the site (34). Ultimately, the newly for-
med capillaries become part of the existing circulation in
a process in which shear stress is a critical factor (35).
Although inﬂammation plays a signiﬁcant role in angio-
genesis, multiple other processes are implicated in develop-
ment of new vessels, including cell-to-extracellular matrix
interactions, vascular wall maturation and basal lamina
modiﬁcations (32,36). The behavior of endothelial cells is
signiﬁcantly inﬂuenced by inﬂammatory leukocytes able to
release the number of proangiogenic factors, such as VEGF,
hepatocyte growth factor, and tumor necrosis factor-
(TNF)-a, and interleukin (IL)-8 (37,38).
In areas of atherogenic lesions chronic infection, cigarette
smoking, free radicals, hypertension, and diabetes have all
been implicated as causes in the activation of endothelial
cells (35,39). The increased shear stress acting through
both membrane structures and cell junction molecules,
stimulate quiescent endothelial cells lining the vascular wall
(40). This intracellular signaling triggers the expression of
genes such as MCP-1 mRNA, involved in induction of
transcription factors responsible for shear stress-mediated
effects (32,34). This sequence of events in the presence of
hypercholesterolemia triggers expression of adhesion mole-
cules, particularly P-selectin, E-selectin, VCAM-1, ICAM-1,
and MCP-1 release and activation of genes responsible
for the expression of CCR2 (MCP-1 receptor) (32,41).
Monocytes in Angiogenesis
Oxygen-deprived intima of the arterial wall recruits circu-
lating monocytes via speciﬁc integrin receptors (macrophageadhesion ligand [Mac]-1), that interacts with the endothelial
adhesion molecules (36,42) (Fig. 2). It has been shown that
this binding predominantly occurs at the tight junctions of
the endothelial cells and allows monocyte entry into the
subendothelial space. VEGF, expressed by macrophages
activates the production of MCP-1 by the endothelial cells
and an increase in the permeability of the endothelial layer
(Table 2) (35). The chronic low-grade inﬂammation inside
the vascular wall has been shown to be associated with
monocyte inﬁltration. The monocyte maturation to macro-
phages is accompanied by the production of cytokines and
growth factors (36,38).
Plaque monocytes/macrophages interact with collagen
and proteoglycans in the extracellular matrix by expressing
proteases such as urokinase plasminogen activator (43).
Urokinase plasminogen activator activates plasmin, which
in turn degrades the extracellular matrix (43). The monocytes
produce platelet-derived growth factor, which in-
duces mitotic activity of the endothelial cells and vascular
smooth muscle cells (44). Activated plaque monocytes/
macrophages ingest the oxidized lipids and become lipid-
laden “foam” cells. It is believed that “foam” cells promote
vascular remodeling by stimulation of smooth muscle cell
migration and a subsequent shift in endothelial function (45).
While there is a distinct relationship between monocytes
and angiogenesis in the atherosclerotic lesions, controversy
surrounds the origin of the native endothelial cells as well
as the role of speciﬁc subtypes of monocyte populations such
as CD14þ/VEGFR-2þ monocytes (46). Animal studies
have demonstrated that although endothelial cells play a role
in the initiation of the atherosclerotic process they them-
selves may be bone marrow-derived as in tumor-associated
blood vessels (47). Once monocytes have inﬁltrated the
tissue layers a proportion of them will differentiate into
dendritic cells triggering the activation of antigen speciﬁc T
lymphocytes associated with creation of the local inﬂam-
matory environment (48).
A large proportion of circulating EPCs was found to be of
monocytic origin (49). Human monocytes include a pop-
ulation of cells able to obtain endothelial cell phenotype
in culture (50). Cultures of so-called “early” EPCs are
mainly comprised of monocytes and T-cells and their
formation is strictly dependent upon monocyte presence
(51). Additionally, monocytes constitute the dominant
population among circulating cells expressing type 2 re-
ceptor for VEGF (VEGFR2) (52). Cells bearing CD14
(a monocyte marker) are capable of improving re-
endothelialization after carotid balloon injury in animals
and this process depends on the levels of a major factor
stimulating monocyte mobilization, MCP-1 (53). Elsheikh
et al. (46) have reported that transplantation of CD14þ/
VEGFR2þ cells into balloon-injured femoral arteries of
nude mice signiﬁcantly contributed to their efﬁcient re-
endothelialization. These data support the possible
involvement of monocytes in hypoxia-induced VEGF-
mediated formation of vasa vasorum (Table 3).
Figure 2 Monocytes Role in Angiogenesis
Pathway from hypoxia to the production of the macrophage foam cell. Ang ¼ angiopoietin; HIF ¼ hypoxia induced factor; LDL ¼ low-density lipoprotein; MAC ¼ macrophage
antigen; MCP ¼ monocyte chemotactic protein; MMP ¼ matrix metalloproteinase; PDGF ¼ platelet-derived growth factor; Tie ¼ tyrosine kinase; VEGF ¼ vascular endothelial
growth factor.
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5Monocyte Heterogeneity
Monocyte subsets in particular are believed to play a differ-
ential role in intra-plaque angiogenesis and tissue repair
(32). The subsets differ in phenotype, granulation, size,
morphology, and genetic make up (54). Over the last 30
years, human monocyte subsets were distinguished based
on their surface CD14/CD16 expression as “classical”
CD14þþCD16– cells and less frequent “nonclassical”
CD14þCD16þþ blood monocytes (55).
A third subset can be distinguished by surface ex-
pression of CCR2 (Table 4) (56). Interestingly, these
CD14þþCD16þCCR2þ monocytes phenotypically
resemble the previously reported pro-angiogenic mono-
cytes (56). For example, De Palma et al. (57) and Venneri
et al. (58) demonstrated distinct pro-angiogenic properties
of tyrosine kinase (Tie) 2–expressing monocytes. This
conclusion lends to an earlier study by Lu et al. (59) on
bone marrow derived vascular progenitors, which demon-
strated blood vessel formation to be an angiogenic process
(from pre-existing vessels) but also having a vasculogenic
component. In other words, growth factors, cytokines, and
other key proangiogenic contributions derive not only from
local tissues but also from bone marrow (59).
The identiﬁcation of each subset thus allows further
research into their respective physiological functions.Ziegler-Heitbrock et al. (60) showed that CD14þCD16þ
monocytes have some features common with mature
tissue macrophages. However, animal-based studies on
monocyte subsets are controversial due to substantial
differences between human and murine monocyte subsets
(61). Nahrendorf et al. (62) compared monocytes in
a model of mouse myocardial infarction and suggested
that speciﬁc signaling may depend on site and type of
hypoxia/ischemia insult and time of recovery from this
injury.
Although 3 monocyte subsets are now recognized, the
majority of published studies only refer to 2 monocyte
subpopulations (i.e., CD14þCD16- and CD14þCD16þ
monocytes) without further subdivision of the CD16þ
cells, and thus careful interpretation of such data is
required. The CD16þ monocytes are infrequent (less than
15% in healthy humans), but their proportions are in-
creased in patients with stenotic coronary artery disease,
and myocardial infarction, being related to the up-
regulation of inﬂammatory cytokines (63,64). These data
may indicate a possible role of CD16þ monocytes for
the advanced inﬂammation-mediated arteriogenesis/intra-
plaque angiogenesis. However, the relation of monocyte
populations to systemic atherosclerosis (intima-media
thickness, adventitial vasa vasorum) and high-risk indices
for plaque destabilization is clearly understudied. Subset
Table 2 Examples of Animal and Human Studies Implicating Monocytes in Angiogenesis
First Author (Ref. #) Model Mediating Factor Study Design Study Finding
Capoccia et al. (65) Mouse MCP-1 Direct injection of bone marrow
cells into blood of surgically induced
hind limb ischemia. Adductor hind leg
muscle was then subjected to ﬂow
cytometry, ELISA, and immunoﬂuorescence.
Bone marrow cells were also harvested and
transplanted into wild-type mice.
Inﬂammatory subset of monocytes was
selectively recruited to the site of insult
in parallel with increased MCP-1 amounts.
Two waves of monocyte proliferation were
demonstrated in the presence of angiogenesis
and inﬂammation.
Arras et al. (102) Rabbit TNF, bFGF Femoral artery occlusion of rabbit hind limb
for 3 and 7 days, with randomly given
lipopolysaccharide. Further control animals
were tested at 21 days for comparison.
Carotid artery catheters were also placed
for proliferation analysis.
After day 7 of induced hypoxia, maximal
macrophage proliferation was present being
associated with higher TNF and bFGF levels.
Monocytes/macrophage activation played
important role in angiogenesis and vessel
growth in the presence of hypoxia.
Hong et al. (30) Rat, chick MCP-1, VEGF Thoracic and abdominal aortas were obtained
from 5-week-old rats. VEGF was analyzed by
mRNA expression using PCR. MCP-1 was
analyzed in vivo using chick chorioallantoic
membrane.
Monocytes were implicated in angiogenesis in
MCP-1–mediated manner and related to HIF
and VEGFA up-regulation.
Cursiefen et al. (103) Mouse VEGF Mouse model of suture induced inﬂammatory
corneal neovascularization. Immunochemistry
and morphometry were used to analyze
angiogenesis in the cornea.
VEGF mediates the recruitment of monocytes/
macrophages resulting in the initiation of
neovascularization in the presence of
inﬂammation but also ampliﬁes the pathological
process of both angiogenesis.
Eubank et al. (104) Human M-CSF, VEGF Isolated human monocytes were stimulated
with M-CSF. ELISA was used for VEGF analysis.
M-CSF enhanced production of VEGF and
angiogenesis by human monocytes.
Venneri et al. (58) Human Tie2 Healthy blood donors and surgically resected
tumor tissue. Analysis performed using ﬂow
cytometry, western-blot analysis,
immunohistochemistry, and migration assays.
Tie2þ monocytes were associated with
angiogenesis.
Ang-2 ¼ angiopoietin; bFGF ¼ basic ﬁbroblast factor; EC ¼ endothelial cell; ELISA ¼ enzyme-linked immunoadsorbent assay; HIF ¼ hypoxia inducible factor; M-CSF ¼ macrophage colony-stimulating factor;
MCP ¼ monocyte chemotactic protein; PCR ¼ polymerase chain reaction; Tie2 ¼ tyrosine kinase; VEGF ¼ vascular endothelial growth factor.
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6speciﬁcity may also be dependent on expression of mul-
tiple receptors and MCP-1–mediated signaling (65).
Indeed, angiogenesis and monocyte subset involvement is a
multiple stepwise process, which consists of 2 areas of
recruitment, local and bone marrow, which are speciﬁc to
the stimulating environment (65). Further studies are being
performed to delineate the speciﬁc functions of each of
the monocyte subsets, but their speciﬁc roles in plaque
progression, stability, and rupture remains insufﬁciently
understood at present.Monocytes in Atherosclerosis Progression
Uncontrolled lipid accumulation followed by rapid mono-
cyte inﬁltration and phagocytosis of low-density lipoprotein-
mediated by scavenger receptors subsequently results inTable 3 Family of VEGF and Their Functions
Type Function
VEGFA Angiogenesis
Chemotactis
Vasodilatation
VEGFB Embryonic
VEGFC Lymphangiogenic
VEGFD Lung lymphatics
PlGF Vasculogenesis
PlGF ¼ placental growth factor; VEGF ¼ vascular endothelial growth factor.macrophage apoptosis. This understandably increases the
atherosclerotic plaque core with ensuing necrotic tissue,
collagen deposition and migration of smooth muscle (32).
This pattern of monocyte/macrophage deposition and
removal although protective by nature is only mediated by
the inﬂammatory reaction that it manifests itself. This
unbalanced inﬂammation with excessive cytokine release from
monocytes and enhancedmonocyte expression of theToll-like
receptors promotes both angiogenesis and plaque growth and
destabilization. Administration of statins to subjects with
hypercholesterolemia inhibited the expression of monocyte
pro-inﬂammatory cytokines (TNF and IL1b) and the
treatment has a well documented capacity to reduce risk of
unfavorable events in patients with stable coronary heart
disease (66). Moreover, long-term treatment with statins
can prevent progression or even lead to regression of the
atheroma, although the relative magnitude of lipid-
independent pleiotropic effects of the statins in the overall
beneﬁts of the drugs remain unclear.Table 4 Monocytes Subsets and Their Functions
Monocyte subset Expression Primary Function
Mon1 (classical) CD14þþCD16–CCR2þ Phagocytosis
Cytokine production
Mon2 (intermediate) CD14þþCD16þCCR2þ Angiogenesis
Mon3 (non-classical) CD14þCD16þþCCR2– Collagen deposition
Anti-inﬂammatory effects
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7Plaque Instability and Rupture
The volatile nature of an atheromatous plaque is responsible
for approximately 60% of symptomatic carotid artery disease
and about 75% of acute coronary events. Neovascularization
has been implicated as a possible contributor to the process
by which an asymptomatic ﬁbroatheromatous plaque
becomes a lesion vulnerable to rupture, although the precise
mechanism of how this occurs remains unclear. As the
plaque progresses, the adventitial vasa vasorum is the site of
initiation of intraplaque vessels formation (67). Indeed, the
presence of neo-vessels within the plaque has been associ-
ated to its rupture (67). In a comparison of stable plaques
to those in both vulnerable and ruptured plaques, there is
a 2- to 4-fold increase in the number of vasa vasorum,
respectively (68). Although plaque deposits themselves may
be localized and unique, the changes found in the arterial
wall vascularization are known to be systemically wide-
spread, lending to the notion of atherosclerosis being a pan-
arterial disease (69). However the factors that trigger the
change, from a nonthreatening to unstable plaque remains
poorly understood.
The synthesis of pro-inﬂammatory molecules such as IL-6
and TNFa, mediated by stimulation of Toll-like receptors
(TLR4) are upgraded by activated monocytes (51). The
interaction(s) between endothelial cells and white blood cells
results in an inﬂammatory cascade resulting from the
interaction among CD14, a monocyte endotoxin receptor,
acting together with a coreceptor, Toll-like receptor, leading
to monocytic activation (70). This monocyte activation
subsequently enhances the afﬁnity of monocyte ligands to
adhesion molecules, thus promoting monocyte–endothelium
adhesion (70). This has been demonstrated by the presence
of microvessels within lipid-rich plaques strongly expressing
adhesion molecules (ICAM-1, VCAM-1) thereby facili-
tating transendothelial migration of inﬂammatory cells
(i.e., monocytes) into the plaque microenvironment (16).Figure 3 Interaction of Tie2 With Vascular Smooth Muscle
Pathway from vascular smooth muscle to cell signaling and relationship to tyrosine phosThis implicates the potential involvement of monocytes and
their role in plaque neovascularization and plaque rupture.Angiopoietins
Homeostasis of the vascular system is supported by secreted
glycoproteins called angiopoietins (Ang) (71). The latter
function as growth factors to aid angiogenesis. However, this
may not necessarily be the case for angiopoietin 1 (Ang1),
which, under speciﬁc conditions, may act as an inhibitor of
the angiogenic process (72).
There are 4 main ligands in the angiopoietin group
(Ang1, Ang2, Ang3, Ang4) (73). Ang1 and Ang2 have
been well studied and have a strong afﬁnity to tyrosine
kinase receptors (74). Both Ang1 and Ang2 can be found in
high concentration in tumors, particularly angiosarcoma
suggesting their role in both tumor angiogenesis and
progression (75). Shim et al. (76) demonstrated differences
between Ang1 and Ang2 in their response to hypoxia. Ang2
was up-regulated in the presence of ischemic tissue whereas
Ang1 was mostly associated with malignancy. However,
both are implicated in the angiogenic processes. The family
of receptors, which primarily maintains Ang inﬂuence and
ability to be expressed in endothelial cells, is a Tie2. Tie2 is
involved in the stabilization of mature blood vessels,
promoting the interaction between endothelial cells and
supporting periendothelial cells (Fig. 3) (77).
Animal studies have shown that absence of either Ang1
or Tie2 results in incomplete vascular development and
death (78). Interestingly, the interaction between Tie1 and
Tie2 remains primarily unclear but it is known that none of
the Ang family members directly binds Tie1, yet Tie2
inhibits Tie1-mediated regulatory control of endothelial
cell function (79).
Hauer et al. (80) have demonstrated an overall reduction of
experimental atheroma after Tie2 inhibition. Consequently,phorylation. Ang ¼ angiopoietin; Tie2 ¼ tyrosine kinase receptor type 2.
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8a relationship between both Ang2 and VEGF and angio-
genesis was shown in genetically modiﬁed mouse studies (81).
Although the angiogenic effects were greater in the
lymphatic tissue rather than in blood vessels, the studies
raised interest in the development in antiangiogenic ther-
apies (81). Recently, Saharinen et al. (82) suggested that
the 2 systems (i.e., mediated by VEGF and Ang) played
different roles in blood and lymphatic vessel growth.
Another study demonstrated not only a link between
both VEGF and Ang2 but also a clear difference in how
they regulated the angiogenic pathways (83). Indeed,
Ang1 has showed an inhibitory role against the actions of
Tie2 in blood vessel maturation while Ang2 expression
counteracted this Ang1 effect, thus promoting vascular
stabilization (84). Once again this antagonist relationship
has sparked interest from both a scientiﬁc and therapeutic
point of view.VEGF
MCP-1, although known primarily to play a role in
inﬂammation has been shown to be a chemokine with
angiogenic properties. Hong et al. (30) demonstrated that
the MCP-1–mediated angiogenic cascade is maintained and
modulated by VEGF (30). Further evidence to this rela-
tionship and the monocyte role in angiogenesis has been
shown by in vitro treatment of human monocytes with
VEGF obtained from tumor cells, resulting in both mono-
cyte activation and migration (85).
VEGF is a pro-angiogenic growth factor primarily
involved in the initiation of new capillary formation (17).
VEGF is involved in embryonic angiogenesis but it is as well
a potent signaling protein, which stimulates vasculogenesis
and angiogenesis in the presence of injury, exercise, and
formation of collaterals (86,87). There are 4 well-known
VEGF derivatives plus 1 placental growth factor (Table 3,
Fig. 4). Interestingly, excessive VEGF expression has beenFigure 4 VEGFs
Family of vascular endothelial growth factors (VEGFs), receptors, and their functions. HIFlinked to the progression of malignancy, and retinal eye
disease (88). VEGF main action, however, is mediated by
binding of tyrosine-kinase receptors (89).
VEGFR2 is essential for endothelial cell survival (90).
Absence of VEGFR2 is incompatible with development of
endothelial and hematopoietic cells in animals (91). In
contrast VEGFR1 is not obligatory for endothelial cell
differentiation but it is required for embryonic development
(92). Interestingly, a possible antagonistic relationship
between VEGFR1 and VEGFR2 has highlighted the in-
tricate relationship between promoting and maintaining
vascular development in ischemia, cancer, and other path-
ological processes (93). Unfortunately, despite the primary
role of VEGFR2 in both vasculogenesis and angiogenesis,
the molecular mechanisms controlling its genetic expression
are still at an early stage of recognition, representing justi-
ﬁcation for renewed focus in the critical process of protein
modulation in a therapeutic respect (88). This is especially
true because it has been demonstrated that tumor genesis
itself involves speciﬁc angiogenic factors based on tumor
type (94).
The Adrenergic System and Angiogenesis
The adrenergic system has been shown to be implicated in
regulation of expression of pro-angiogenic factors and
angiogenesis (95). For instance, high norepinephrine levels
are linked to increased VEGF expression (96). Although
the mechanisms of norepinephrine-mediated VEGF up-
regulation in atherosclerosis remain unclear, a post-
transcriptional mechanism has been revealed by which
norepinephrine-induced HIF-1a production modulated
VEGF expression in cancer cells (97).
In the absence of ischemia or even exercise, the alpha
adrenergic system has been demonstrated to increase capil-
lary blood ﬂow via an increase in capillarity of skeletal
muscles (98). The alpha adrenergic system has been shown
to inhibit angiogenesis by interfering with endothelial¼ hypoxia induced factor; VEGFR ¼ vascular endothelial growth factor receptor.
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9cell proliferation and responsiveness to VEGF. Although
expressed in many tissues, the primary role of beta adren-
ergic system (b2A) receptors overall remains unclear. Leosco
and colleagues (99) demonstrated the promotion of angio-
genesis with exercise resulting in improved b2A signaling.
In the presence of ischemia, adrenergic down-regulation
of b2A with enhancement and preservation of capillaries
along with the promotion of endothelial cell proliferation
suggests a vital role in regulation of angiogenesis by the b2A
system (100). Most recently emphasis has been placed on
identiﬁcation of speciﬁc b2A receptor subtypes on lipo-
polysaccharide laden monocytes implicated in creation of
the pro-inﬂammatory state, mediated by cytokine modu-
lation and cyclic adenosine monophosphate–dependent
mechanisms (101).Conclusions
Atherosclerosis and its angiogenic component is an obvious
feature of vascular disease. The regeneration of vascular beds
with capillary sprouting relies on angiogenesis. Atheroscle-
rosis has an inﬂammatory component, and MCP-1 plays
a role in recruiting monocytes to the site of insult. Mono-
cytes, important members of the innate immune system
have been shown to play an intricate role in angiogenesis.
Neovascularization is a major contributor to plaque pro-
gression. Much more research is required to establish the
exact mechanisms underlying the tightly regulated angio-
genic processes. One approach would be to continue to
investigate the potential presence of various subtypes of
monocytes and their speciﬁc receptors and roles in cardio-
vascular disease. This hopefully would be useful for the
development of new therapeutic targets for prevention of
progression of atherosclerotic disease and its complications.
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